ArticleMolecular medicine reports2021
miR‑212 promotes renal interstitial fibrosis by inhibiting hypoxia‑inducible factor 1‑α inhibitor.
Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Article
- Yishen-Huoxue formula alleviates renal interstitial fibrosis by attenuating hypoxia-induced renal cell injury and promoting angiogenesis via miR-210/HIF-1α pathway.Frontiers in medicine · 2025Article
- Novel Peptide DR3penA as a Low-Toxicity Antirenal Fibrosis Agent by Suppressing the TGF-β1/miR-212-5p/Low-Density Lipoprotein Receptor Class a Domain Containing 4/Smad Axis.ACS pharmacology & translational science · 2024Article
- Mechanism of Tao Hong Decoction in the treatment of atherosclerosis based on network pharmacology and experimental validation.Frontiers in cardiovascular medicine · 2023Article
- Upregulated microRNA-429 confers endometrial stromal cell dysfunction by targeting HIF1AN and regulating the HIF1A/VEGF pathway.Open medicine (Warsaw, Poland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal interstitial fibrosis is one of the common causes, and a major pathological basis for the development of various types of chronic progressive renal to end‑stage renal diseases. Therefore, it is important to clarify the underlying mechanisms of disease progression in order to develop effective strategies for the treatment and prevention of these pathologies. The aim of the present study was to investigate the association between microRNA (miR)‑212 expression and the development of renal interstitial fibrosis, as well as analyzing the role of miR‑212 in the disease. The expression of miR‑212 was significantly increased in the peripheral blood of patients with renal interstitial fibrosis and in the kidney tissues of unilateral ureteral obstruction (UUO) mice. Angiotensin (Ang) II, TGF‑β1 and hypoxia were found to increase the expression of miR‑212 and α smooth muscle actin (α‑SMA) in NRK49F cells. Ang II stimulation induced the expression of miR‑212 and α‑SMA in NRK49F cells, while transfection of miR‑212 mimics further upregulated the expression of α‑SMA. miR‑212 was also revealed to target hypoxia‑inducible factor 1α inhibitor (HIF1AN) and to upregulate the expression of hypoxia‑inducible factor 1α, α‑SMA, connective tissue growth factor, collagen α‑1(I) chain and collagen α‑1(III) chain, whereas HIF1AN overexpression reversed the regulatory effects of miR‑212. In UUO mice, miR‑212 overexpression promoted the progression of renal interstitial fibrosis, whereas inhibiting miR‑212 resulted in the opposite effect. These results indicated that high expression of miR‑212 was closely associated with the occurrence of renal interstitial fibrosis, and that miR‑212 may promote its development by targeting HIF1AN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.